Publications by authors named "Peter Ackerman"

Claim this Profile
P
Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patients.
Ridhi Parasrampuria, Nilay Thakkar, Katy Moore, Peter Ackerman, Mindy Magee

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
Nneka Nwokolo, Elana Post, A Savannah Mageau, Rimi Shah, Mindy Magee, Peter Ackerman

HIV Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interprofessional In Situ Simulation to Identify Latent Safety Threats for Quality Improvement: A Single-Center Protocol Report.
Cairenn Binder, Diana Elwell, Peter Ackerman, Jodi Shulman, Christina Yang

J Emerg Nurs· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection.
Mark Krystal, Shiven Chabria, Daren Austin, Allen Wolstenholme, David Wensel, Peter Ackerman

Antivir Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg, Peter Ackerman

Antimicrob Agents Chemother· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
Peter Gorycki, Mindy Magee, Peter Ackerman, Xiusheng Miao, Katy Moore

Xenobiotica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Peter Ackerman

Antimicrob Agents Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Sarah-Jane Anderson, Miranda Murray, David Cella, Robert Grossberg, Debbie Hagins, Peter Ackerman

Patient· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
Ronald Rose, Margaret Gartland, Zhufang Li, Nannan Zhou, Mark Cockett, Peter Ackerman

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore

HIV Res Clin Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
Margaret Gartland, Eric Arnoult, Brian T Foley, Max Lataillade, Peter Ackerman

J Antimicrob Chemother· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
Mindy Magee, Jill Slater, Frank Mannino, Peter Ackerman, Cyril Llamoso

J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
Peter Ackerman, Melanie Thompson, Jean-Michel Molina, Judith Aberg, Isabel Cassetti

AIDS· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
Margaret Gartland, Nannan Zhou, Eugene Stewart, Amy Pierce, Andrew Clark, Peter Ackerman

J Antimicrob Chemother· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Max Lataillade, Jacob P Lalezari, Michael Kozal, Judith A Aberg, Gilles Pialoux, Peter Ackerman

Lancet HIV· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
Chakradhar Lagishetty, Katy Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee

Clin Transl Sci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Michael Kozal, Judith Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Peter Ackerman

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Katy Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin, Peter Ackerman

Br J Clin Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, Juan Berenguer, Natalia Zakharova, Peter Ackerman

Hepatol Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Anne F Luetkemeyer, Cheryl McDonald, Moti Ramgopal, Stephanie Noviello, Rafia Bhore, Peter Ackerman

Clin Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.
Maureen M Jonas, Mei-Hwei Chang, Etienne Sokal, Kathleen B Schwarz, Deirdre Kelly, Peter Ackerman

Hepatology· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Elyse Swallow, Jinlin Song, Yong Yuan, Anupama Kalsekar, Caroline Kelley, Peter Ackerman

Clin Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
David L Wyles, Peter J Ruane, Mark S Sulkowski, Douglas Dieterich, Anne Luetkemeyer, Peter Ackerman

N Engl J Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island.
Francine Touzard Romo, Fizza S Gillani, Peter Ackerman, Aadia Rana, Erna M Kojic

R I Med J (2013)· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disaster-proofing your practice. Preparation is key.
Peter J Ackerman

CDS Rev· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis